Add to Basket
|+1 404 474 4654|
|+1 888 205 9894 (TF)|
Chemokine (C-C Motif) Ligand 2 (CCL2) (N-Term,AA 24-36) antibody
|Synonyms||HC11, MCAF, MCP1, MCP-1, SCYA2, GDCF-2, SMC-CF, HSMCR30, MGC9434, JE, Scya2, Sigje, AI323594, CCL2, DKFZp469C111|
Human, Mouse (Murine), Rat (Rattus)
Alternatives Western Blotting (WB)
|3 references available|
|Price||316.25 $ Plus shipping costs $45.00|
|Availability||Will be delivered in 5 to 7 Business Days|
|Immunogen||A synthetic peptide corresponding to a sequence at the N-terminal of human MCP-1 (24-36 aa), different from the mouse sequence by two amino acids.|
|Reconstitution||0.2ml of distilled water will yield a concentration of 500µg/ml.|
|Description||Monocyte chemoattractant protein-1 (MCP-1), a member of the chemokine (chemotactic cytokine) family, is a potent monocyte agonist that is upregulated by oxidized lipids.1 MCP-1 is also known as CCL2, SCYA2, MCAF. MCAF is a member of family of factors involved in immune and inflammatory responses. The amino acid sequence deduced from the nucleotide sequence reveals the primary structure of the MCAF precursor to be composed of a putative signal peptide sequence of 23 amino acid residues and a mature MCAF sequence of 76 amino acid residues.2 MCP-1 plays a unique and crucial role in the initiation of atherosclerosis and may provide a new therapeutic target in this disorder.3 Human MCP-1 is a 8.7KDa non-glycoprotein, consisting of 99 amino acids in precursor form and 76 amino acids in mature form.|
|Buffer||Each vial contains 5mg BSA, 0.9mg NaCl, 0.2mg Na2HPO4|
|Preservative||0.05mg Thiomersal, 0.05mg NaN3.|
|Storage||At -20°C for one year. After reconstitution, at 4°C for one month.|
|Restrictions||For Research Use only|
Furutani, Nomura, Notake et al.: "Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF)." in: Biochemical and biophysical research communications, Vol. 159, Issue 1, pp. 249-55, 1989 (PubMed).
Gu, Okada, Clinton et al.: "Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice." in: Molecular cell, Vol. 2, Issue 2, pp. 275-81, 1998 (PubMed).
Gosling, Slaymaker, Gu et al.: "MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B." in: The Journal of clinical investigation, Vol. 103, Issue 6, pp. 773-8, 1999 (PubMed).